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Summary
In a BCR/ABL-expressing myeloid precursor cell line, p53 levels were markedly downmodulated. Expression of MDM2,
the negative regulator of p53, was upregulated in a tyrosine kinase-dependent manner in growth factor-independent BCR/
ABL-expressing cells, and in accelerated phase and blast crisis CML samples. Increased MDM2 expression was associated
with enhanced mdm2 mRNA translation, which required the interaction of the La antigen with mdm2 5 UTR. Expression
of MDM2 correlated with that of La and was suppressed by La siRNAs and by a dominant negative La mutant, which also
enhanced the susceptibility to drug-induced apoptosis of BCR/ABL-transformed cells. By contrast, La overexpression led
to increased MDM2 levels and enhanced resistance to apoptosis. Thus, La-dependent activation of mdm2 translation might
represent an important molecular mechanism involved in BCR/ABL leukemogenesis.
Introduction duced by BCR/ABL-expressing hematopoietic cells is sup-
pressed upon downregulation of BCR/ABL levels or inhibition
Chronic myelogenous leukemia (CML) is a clonal disorder aris- of protein function (Skorski et al., 1996a; Huettner et al., 2000;
ing from neoplastic transformation of the hematopoietic stem Druker et al., 1996); recent data in CML-blast crisis (BC) patients
cells (Kantarjian et al., 1993). The typical course of CML involves indicate that temporary clinical remission is achieved by treat-
progression from a protracted chronic phase, marked by accu- ment with the ABL kinase inhibitor STI571 (Druker et al., 2001).
The reliance of CML-BC cells on BCR/ABL activity for theirmulation of apparently normal neutrophils, to a rapidly fatal
blast crisis characterized by clonal expansion of differentiation- proliferation and survival is consistent with the reported en-
hanced expression of BCR/ABL in these cells (Gaiger et al.,arrested myeloid precursor cells. The BCR/ABL oncoproteins,
the leukemia-specific gene products of the Philadelphia chro- 1995; Elmaagacli et al., 2000; Wetzler et al., 1993). In some
cases, such an increase in BCR/ABL levels might be causedmosome (Ph1) translocation, are responsible for transformation
of the hematopoietic stem cell through their deregulated tyro- by a double Philadelphia1 chromosome, which is a relatively
common secondary genetic change during disease progressionsine kinase activity; such activity is essential for recruitment and
activation of multiple pathways that transduce signals leading (Kantarjian et al., 1987).
Inactivating mutations of the p53 gene are rarely found into enhanced proliferative potential and survival of BCR/ABL-
expressing hematopoietic precursor cells (Gordon, 1999; Osa- chronic phase, but are relatively common in the blast crisis
disease stage of CML (Feinstein et al., 1991), suggesting thatrogiagbon and McGlave, 1999; Sawyers, 1999). There is also
evidence that BCR/ABL expression is required for maintenance loss of function of p53 plays an important role in disease pro-
gression. Indeed, loss of wild-type p53 potentiates the leuke-of the leukemic phenotype. In mice, the disease process in-
S I G N I F I C A N C E
BCR/ABL oncoproteins enhance survival of hematopoietic cells by regulating the expression and/or the activity of anti- or proapoptotic
proteins. In 30% of CML-blast crisis, p53 is genetically inactivated, and p53//BCR/ABL marrow cells induce aggressive leukemia
in mice, suggesting that genetic or functional p53 inactivation is important in CML disease progression. Here we show that BCR/ABL
enhances expression of MDM2, the negative regulator of p53, by inducing the expression of the La antigen that, in turn, activates
mdm2 translation upon binding to its mRNA. In BCR/ABL cells, interference with La activity resulted in decreased MDM2 and increased
adriamycin sensitivity. The importance of La in regulation of MDM2 emphasizes the relevance of translation regulatory pathways in
the activity of BCR/ABL and, possibly, of other oncogenic tyrosine kinases.
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mia-inducing effects of BCR/ABL, as indicated by the enhanced
leukemogenic potential of BCR/ABL-expressing p53-deficient
marrow cells (Skorski et al., 1996b; Honda et al., 2000). Since
genetic inactivation of p53 is detected in approximately 25%
of CML-BC patients (Feinstein et al., 1991), p53 might be func-
tionally inactivated in some of the patients with a wild-type
gene. Studies of p53 expression in CML have been complicated
(Lubbert et al., 1988; Kastan et al., 1991; Bi et al., 1994), in part
by the fact that the nonfunctional mutant p53 is more stable
than wild-type p53, and in part because marrow samples of
CML patients often include normal cells with wild-type p53.
Nonetheless, some evidence suggests that BCR/ABL may neg-
atively regulate p53 in CML, since expression of wild-type p53
is undetectable in certain Philadelphia1 cell lines (Lubbert et al.,
1988), and p53 levels become undetectable upon expression
of BCR/ABL in a mouse hematopoietic progenitor cell line
(Pierce et al., 2000). It has been well established that MDM2
negatively regulates p53 (Haupt et al., 1997; Kubbutat et al.,
1997), in part by interacting with p53 in the nucleus (Momand
et al., 1992) to inhibit its transcription activation function, and
also by promoting p53 export and proteasome-dependent deg-
radation in the cytoplasm (Tao and Levine, 1999; Fang et al.,
2000b; Geyer et al., 2000; Boyd et al., 2000).
Since mdm2 is overexpressed in approximately 50% of pa-
tients with hematological malignancies and is associated with
poor prognosis and chemotherapeutic drug resistance (Seliger
et al., 1996; Faderl et al., 2000; Zhou et al., 1995, 2000), we
asked whether BCR/ABL might induce an increase in MDM2
expression that would lead to functional inactivation of p53.
While this work was in progress, a study reported that: (1) MDM2
levels were increased in a BCR/ABL-expressing cell line, and
(2) MDM2 downmodulation by antisense oligonucleotides pro-
moted growth factor deprivation-induced apoptosis (Goetz et
al., 2001). However, the mechanisms underlying the enhanced
MDM2 expression were not analyzed in detail (Goetz et al.,
2001). We report here that BCR/ABL induces an increase of
MDM2 expression by enhancing mdm2 mRNA translation via
an RNA binding protein, identified by mass spectrometry and
microsequencing as the La antigen, which recognizes a 27 nu-
cleotide segment in the 5 untranslated region of mdm2 mRNA.
In BCR/ABL-expressing 32Dcl3 cells as well as in primary mono-
nuclear marrow cells of CML-BC patients, La expression corre-
lated with that of MDM2. A dominant negative La antigen mutant
inhibited mdm2 mRNA translation in vitro and suppressed
MDM2 expression in BCR/ABL-expressing cells. Likewise, La Figure 1. Effects of BCR/ABL on p53 expression
downmodulation by RNA interference led to markedly de- A: p53 nuclear protein (upper panel) and mRNA (3rd panel) levels were
creased MDM2 levels. By contrast, overexpression of wild-type detected by Western and Northern blot, respectively, in parental (lane 3)
and newly established BCR/ABL clones (lanes 1 and 2). Histone H1 and rRNALa increased MDM2 levels in 32D-BCR/ABL cells. Together,
levels were monitored as controls for loading.these data suggest that the BCR/ABL oncoproteins can func-
B: Effect of the proteasome inhibitor lactacystin (Lact.) and nuclear exporttionally inactivate p53 by enhancing MDM2 levels via La-depen-
inhibitor Leptomycin B (LMB) on endogenous p53 expression in parental
dent upregulation of mdm2 mRNA translation. and BCR/ABL-expressing 32Dcl3 cells.
C: Effect of adriamycin (alone or in combination with the proteasome inhibi-
tor ALLN) on p53 expression in parental and BCR/ABL-expressing 32Dcl3Results
cells.
In B and C, HSP90 was monitored as a loading control, and treatment times
p53 expression in BCR/ABL-expressing 32Dcl3 are indicated below the lanes.
Myeloid precursor 32Dcl3 cells express wild-type p53 (Blandino
et al., 1995). p53 protein levels were detectable in nuclear ex-
tracts of parental 32Dcl3 cells, while newly derived BCR/ABL-
expressing 32Dcl3 cells showed markedly less expression, de-
spite nearly identical levels of p53 mRNA (Figure 1A). Since
the primary mechanism regulating p53 levels is proteasome-
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Figure 2. Expression of MDM2 in parental and
BCR/ABL-expressing 32Dcl3 cells, and in mono-
nuclear cells from patients with CML in chronic
phase (CML-CP), accelerated phase (CML-AP),
and blast crisis (CML-BC)
A: left, mdm2 expression (protein and mRNA) in
parental and BCR/ABL-expressing 32Dcl3 cells
(lanes 1–4); right, MDM2 levels in mononuclear
marrow cells from multiple patients with CML-CP
(lanes 10–12), CML-BC (lanes 6–9), and during
disease progression from CML-CP to CML-BC in
two patients (#12 and 13) (lanes 13–16) as indi-
cated; 32D-BCR/ABL cells (lane 5) served as posi-
tive control; HSP90, GRB2, and ethidium bromide-
stained total RNA served as loading controls.
B: MDM2 (protein and mRNA) and BCR/ABL ex-
pression in untreated and STI571-treated (24 hr)
32D-BCR/ABL cells (lanes 2 and 3), and in the
CD34 and CD34 fraction of mononuclear cells
from a CML-AP patient (lanes 4 and 5). Lanes 6
and 7 show MDM2 levels in untreated and STI571-
treated (24 hr) CML-AP CD34 cells. GRB2 and
HSP90 levels served as loading control. Levels of
mdm2, GRB2, and BCR/ABL transcripts in the
CD34 and CD34 fractions were revealed by
RT-PCR.
dependent degradation in the cytoplasm (Haupt et al., 1997; levels of p53-regulated p21, BAX, and MDM2 in parental and
BCR/ABL-expressing cells (not shown). These results suggestKubbutat et al., 1997; Freedman and Levine, 1998), p53 levels
were assessed in parental and BCR/ABL-expressing 32Dcl3 that an enhanced p53 degradation pathway counteracts the
potential for high p53 expression in BCR/ABL-expressing cells.cells treated with the proteasome inhibitor lactacystin and with
leptomycin B (LMB), a specific inhibitor of nuclear export pre-
viously shown to prevent MDM2-dependent p53 degradation Effects of BCR/ABL on MDM2 expression
p53 levels are primarily regulated via MDM2-dependent degra-(Freedman and Levine, 1998). Western blots of whole cell ex-
tracts revealed low levels of p53 in untreated parental and BCR/ dation (Haupt et al., 1997; Kubbutat et al., 1997). To assess
whether MDM2 expression is regulated by BCR/ABL, WesternABL-expressing cells, but markedly higher levels in cells treated
with lactacystin or LMB (Figure 1B). Expression of p53 was also blot analysis was performed using total extracts from parental
and BCR/ABL-expressing 32Dcl3 cells. Expression of MDM2tested upon treatment with adriamycin, a cytotoxic drug known
to promote a transient increase in p53 levels by suppressing was barely detectable in parental cells (Figure 2A, lane 1), but
markedly increased in 32D-BCR/ABL newly derived cell clonesits degradation (Lakin and Jackson, 1999). As expected, adria-
mycin induced an increase in p53 levels in both parental and (Figure 2A, lanes 2–4) and in a 32D-BCR/ABL established cell
line (Figure 2A, lane 5). By contrast, mdm2 mRNA levels wereBCR/ABL-expressing cells (Figure 1C). In BCR/ABL-expressing
cells, the increased p53 expression was more pronounced and similar in parental and BCR/ABL-expressing cells (Figure 2A).
Thus, overexpression of MDM2 in BCR/ABL-expressing cellsmore transient, as p53 levels were markedly downmodulated 6
and 12 hr after adriamycin treatment (Figure 1C); by contrast, is not due to increased transcription or enhanced mdm2 mRNA
stability. Two forms of mdm2 mRNA have been describedin parental 32Dcl3 cells, p53 levels remained constant after
adriamycin treatment for 3–12 hr (Figure 1C) and were downmo- (Brown et al., 1999): a long form (L-mdm2) that contains a 5
leader with two upstream open reading frames (uORFs) deriveddulated only after 24 hr (not shown). Treatment with the protea-
some/calpain inhibitor ALLN prevented the downmodulation of from exon 1, and a short form (S-mdm2) that has a 5 leader
sequence derived from exon 2. Thus, we performed RT-PCRp53 detected in BCR/ABL-expressing cells 6 and 12 hr after
adriamycin treatment (Figure 1C). Adriamycin treatment induced on DNase I-treated RNA using the appropriate set of primers
to detect both forms. S- and L-mdm2 transcripts were detectedthe expression of a functional p53, as indicated by the increased
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Figure 3. MDM2 half-life, synthesis, and polysome distribution in parental and BCR/ABL-expressing cells
A: MDM2 levels in cycloheximide-treated parental and 32D-BCR/ABL cells. MDM2 half-life was calculated using a described algorithm (Luscher and
Eisenman, 1988).
B: MDM2 levels in anti-MDM2 immunoprecipitates of ALLN-treated parental and BCR/ABL-expressing cells. (*) Asterisk indicates Ig-G heavy chains.
C: Upper panel, levels of newly synthesized MDM2 in anti-MDM2 immunoprecipitates of 35S methionine-labeled parental and BCR/ABL-expressing cells
(lanes 3 and 4). Lanes 1 and 2 show control preclearings. Lower panel, levels of MDM2 by anti-MDM2 Western blotting of preclearings and anti-MDM2
immunoprecipitates.
D: Polysome/monosome distribution of mdm2 and -actin mRNA. Extracts were prepared from untreated and STI571-treated 32D-BCR/ABL cells and
separated by sucrose gradient centrifugation. The relative amount of mdm2 and -actin mRNA in each fraction was determined by Northern blot (middle
panel). The A254 profile and the position of the fractions corresponding to the peak of monosomes and polysomes indicated as 80S and 5-mer, respectively,
are shown. Ethidium bromide staining of gel-fractionated RNA fractions (lower panel).
at similar levels in RNA from parental and BCR/ABL-expressing STI571 also inhibited MDM2 protein, but not mRNA, expression
in CD34 cells from a patient with CML in accelerated phasecells (not shown), further indicating that BCR/ABL-dependent
MDM2 overexpression is not due to increased mRNA levels. (CML-AP) (Figure 2B, lanes 6 and 7). Of note, expression of
MDM2 was detected in mononuclear CD34 but not in mononu-MDM2 levels were also analyzed in mononuclear CML mar-
row samples: in CML-BC samples, MDM2 expression was clear CD34 cells and correlated with that of BCR/ABL activity
(Figure 2B, lanes 4 and 5). By contrast, mdm2 and BCR/ABLabundant, while in CML-chronic phase (CP) samples, it was
virtually undetectable (Figure 2, lanes 6–12). Of note, MDM2 transcripts were detected at similar levels in the CD34 and
CD34 fraction (Figure 2B, lanes 4 and 5, lower panels).expression increased during CML disease progression (Figure
2, lanes 13–16) and correlated with that of BCR/ABL, which
was also more abundant in CML-BC samples (not shown). The Translational regulation of mdm2 expression
increased expression of MDM2 in BCR/ABL-expressing cells in BCR/ABL-expressing cells
was dependent on BCR/ABL kinase activity, as indicated by The MDM2 protein exhibits a short half-life of approximately
the rapid downmodulation of MDM2 protein, but not mdm2 15–30 min (Olson et al., 1993). To determine whether an ex-
mRNA, in cells treated with the ABL kinase inhibitor STI571 (1 tended half-life may account for the BCR/ABL-dependent over-
M; 24 hr) (Figure 2B, compare lanes 2 and 3). At this concentra- expression of MDM2, we monitored MDM2 levels in parental
tion, the inhibitor suppressed the autophosphorylation activity and BCR/ABL-expressing 32Dcl3 cells treated for different
times with the protein synthesis inhibitor cycloheximide (20of BCR/ABL without significant effect on its protein levels.
148 CANCER CELL : FEBRUARY 2003
A R T I C L E
Figure 4. Translational regulation of mdm2 ex-
pression in parental and BCR/ABL-expressing
cells
A: Schematic diagram of mdm2 cDNA plasmids
carrying segments of decreasing length of the
5 untranslated region and an HA-epitope at the
3 end of mdm2 cDNA.
B: Anti-HA Western blots of MDM2 levels (upper
panel) in GFP-positive parental and BCR/ABL-
expressing 32Dcl3 cells retrovirally transduced
with the mdm2 cDNA plasmid (lanes 1–10) shown
in A. Western blot shows the effect of STI571 on
ectopic MDM2 expression (lanes 11 and 12). RNA
levels of ectopic mdm2-HA and GRB2 transcripts
(lower panels) were measured by RT-PCR.
g/ml). Analysis of MDM2 expression in untreated and cyclo- tions after STI571 treatment (Figure 3D). By contrast, the poly-
some/monosome distribution of-actin was not affected (Figureheximide-treated cells indicates that MDM2 has similar stability
in both cell lines (Figure 3A). Indeed, the half-life of MDM2 3D). Thus, BCR/ABL-dependent signals appear to induce in-
creased MDM2 expression by enhancing mdm2 mRNA transla-was approximately 13.5 and 15 min in parental and BCR/ABL-
expressing cells, respectively. In parental and BCR/ABL- tion. In choriocarcinoma cells overexpressing MDM2, L-mdm2
mRNA, which contain two upstream open reading framesexpressing cells, MDM2 levels markedly increased upon treat-
ment with the proteasome inhibitor ALLN, consistent with an (uORFs), were found in the monosome fractions, while the S-
mdm2 transcripts (which lack the uORFs) were preferentiallyactive process of degradation in both cell lines (Figure 3B). Thus,
BCR/ABL-induced MDM2 overexpression does not seem to detected on polysomes (Brown et al., 1999). To examine the
roles of the two uORFs (exon 1) and the intercistronic regiondepend on increased protein stability. Enhanced translation of
mdm2 mRNA has been shown to be a mechanism leading to (exon 2) for mdm2 translation, MDM2 levels were assessed in
green fluorescent protein (GFP)-sorted parental and BCR/ABL-MDM2 overexpression (Landers et al., 1994; Capoulade et al.,
1998). To assess whether the BCR/ABL-induced increase of expressing 32Dcl3 cells after infection with a GFP-expressing
retrovirus carrying the HA-tagged full-length mdm2 cDNA (WT-MDM2 levels reflects an enhanced rate of synthesis, parental
and BCR/ABL-expressing cells were pulse-labeled with 35S- uORF) or the mdm2 cDNA deleted of: the uORFs and intercis-
tronic region (Ex.1/Ex.2); the exon 1 and the initial 51 (Ex.1/methionine, and levels of newly synthesized MDM2 were de-
tected by immunoprecipitation. Newly synthesized MDM2 was Ex.2 -86/-36) or 25 (Ex.1/Ex.2-86/-62) nucleotides of exon
2; or only exon 1 (Ex.1) (Figure 4A). In three different experi-readily detectable in BCR/ABL-expressing, but not in parental,
32Dcl3 cells (Figure 3C). To further assess the translation regula- ments, expression of HA-tagged MDM2 was undetectable in
parental 32Dcl3 cells, but readily detectable in BCR/ABL-ex-tion of MDM2 expression, we assessed polysome- (efficiently
translated) and monosome- (poorly translated) associated pressing cells (Figure 4B). In BCR/ABL-expressing cells, ectopic
expression of MDM2 was similar in cells transduced with WTmdm2 mRNA in untreated and STI571-treated (2 M; 12 h)
BCR/ABL-expressing cells. Upon Northern blot hybridization of uORF,Ex.1, orEx.1/Ex.2(-86/-62), but undetectable in cells
transduced with either Ex.1/Ex.2 (-86/-36) or Ex.1/Ex.2polysome- and monosome-associated RNA separated by linear
sucrose gradient centrifugation, mdm2 mRNA was predominant mdm2-HA construct (Figure 4B). In 32D-BCR/ABL cells trans-
duced with the WT uORF mdm2-HA retrovirus, expression ofin the polysome-associated fractions of BCR/ABL-expressing
cells, whereas it was clearly shifted toward the monosome frac- HA-tagged MDM2 was suppressed by STI571 treatment (1 M;
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Figure 5. Characterization of the mdm2 mRNA-protein complex in BCR/ABL-expressing cells
A: Schematic diagram of murine mdm2 intercistronic region (exon 2) and of the ssODNs and RNA-oligomers used either as competitors or as probes in UV
crosslinking assays. Sequence alignment shows homology between mouse and human mdm2 exon 2 RNA oligoribonucleotides.
B: Left, UV crosslinking with the murine mdm2 intercistronic riboprobe and cytoplasmic extracts from parental or BCR/ABL-expressing cells in the absence
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48 hr) (Figure 4B, lanes 11 and 12), further supporting the essen- man cells (Figure 5B, lanes 12–14) and, as expected, unlabeled
murine or human RNA-oligo 2 inhibited formation of both humantial role of BCR/ABL in enhancing MDM2 expression by a trans-
lational mechanism. and mouse mdm2 complex A, respectively (Figure 5B, lanes 9,
11, 13, and 15). These data indicate that an RNA binding protein,Transcripts of ectopically expressed HA-tagged mdm2 were
detected at similar levels in 32Dcl3 and 32D-BCR/ABL-express- conserved in mouse and human cells, recognizes a conserved
central segment of the mdm2 intercistronic region that wasing cells (Figure 4B, lower panels), indicating that the differences
in MDM2-HA levels in retrovirus-transduced cells depend on shown above to be required for efficient translation of mdm2
mRNA in BCR/ABL-transformed cells.posttranscriptional mechanisms.
To further validate the use of the mdm2-HA constructs,
32D BCR/ABL cells transduced with WT-uORF mdm2-HA were The La antigen interacts with mdm2 mRNA and
mediates MDM2 expression in vitro and in vivotreated with adriamycin (1 g/ml, 3 hr) and ALLN (25 M, 3 hr)
to induce p53 expression and prevent its degradation, respec- The mdm2 RNA binding protein responsible for complex A (Fig-
ure 5B) was purified from K562 cytoplasmic extracts by RNAtively. As expected, whole-cell lysates of these cells showed
high levels of HA-tagged MDM2 and p53 expression (not affinity chromatography using a 5 biotinylated mdm2 RNA-
oligo-2 coupled to streptavidin-sepharose. The purified protein,shown), and anti-HA Western blotting of anti-p53 immunopre-
cipitates revealed that HA-tagged MDM2 is in complex with examined by Coomassie blue staining, exhibited efficient bind-
ing to 32P-RNA-oligo 2; 1 ng of the purified protein was equivalentendogenous p53 (not shown), indicating that ectopic MDM2
contains an intact p53 binding domain. to 15 g of K562 cytoplasmic extracts in its RNA binding
activity (Figure 5B, lane 16). Mass spectrometry and micro-
sequencing of the mdm2 mRNA binding protein identified sev-A 50 kDa RNA binding protein interacts with the
intercistronic region of mdm2 mRNA eral peptide sequences identical to the human La antigen. The
La antigen is an RNA binding protein involved in the biogenesisThe experiments shown above are consistent with the possibility
that BCR/ABL regulates an RNA binding protein that interacts and processing of RNA polymerase III transcripts and has also
been shown to stimulate mRNA translation (Maraia and Intine,with the intercistronic region of mdm2 mRNA to stimulate mdm2
mRNA translation. Thus, a riboprobe containing the intercis- 2001; Wolin and Cedervall, 2002).
To determine whether the La antigen is the BCR/ABL-regu-tronic region (89 bases) of mdm2 mRNA (mdm2 exon 2) (Figure
5A) was tested in an UV-crosslinking assay for the ability to lated protein interacting with RNA-oligo 2, cytoplasmic extracts
from 32Dcl3 cells ectopically expressing the full-length humanbind protein(s) in cytosolic extracts from parental and BCR/
ABL-expressing 32Dcl3 cells, as well as from the Ph1 K562 La cDNA were subjected to RNA UV crosslinking. As expected,
complex A was detectable in La-expressing 32Dcl3 cells (Figureerythroleukemia cell line. An RNA-protein complex (mdm2 com-
plex “A”) was readily detected in lysates from murine BCR/ABL- 5B, lane 17). Importantly, complex A was no longer detectable
using La-immunodepleted K562 cell extracts (compare lanes 18expressing cells (Figure 5B, lane 3), but was barely detectable
in lysates from parental 32Dcl3 cells (Figure 5B, lane 2). In and 19), confirming that La is required for complex A formation.
Bacterially expressed GST-La protein also interacted with theUV crosslinking assays, a 1000-fold excess of 35-base single-
stranded oligodeoxynucleotides ssODN1, ssODN2, and ssODN3 32P-labeled mdm2 RNA-oligo 2 (Figure 5B, lane 20); by contrast,
an N- and C-terminal truncated La protein (aa 226–348) which(corresponding to the 5, middle, and 3 portion of mdm2 exon
2, respectively) were used to examine the specificity of the lacks the RNA binding domain did not interact with the mdm2
oligoribonucleotide (Figure 5B, lane 21), as expected.binding complex. Formation of mdm2 complex A was specifi-
cally competed by ssODN2, but not by ssODN1 or ssODN3 A specific physical association between La and mdm-2
mRNA was also demonstrated in 32D-BCR/ABL cell lysate by(Figure 5B, lane 5). Thus, UV-crosslinking experiments were
carried out using the 32P-labeled mouse oligoribonucleotide RT-PCR after immunoprecipitation (IP) with anti-La, but not pre-
immune, serum (Figure 5C). mdm-2 mRNA was readily detected(RNA-oligo 2) corresponding to ssODN2; once again, mdm2
complex A was detected in mouse and human BCR/ABL- in the anti-La IP (lane 6) but not in the preimmune IP (lane 5).
As expected, mdm2 mRNA was also detected in total RNAexpressing cells, but not in 32Dcl3 cells (Figure 5B, lanes 8
and 10). Sequence comparison of mouse and human mdm2 prepared from the 32D-BCR/ABL cell extracts used for IPs (in-
put, lane 1). Moreover, preimmune serum did not deplete mdm-2intercistronic regions revealed identical size (89 bases), but wide
divergence except in their central segment (RNA-oligo 2) (Figure mRNA from the extract (upper panel, lane 3), while anti-La did
(lane 4). It is noteworthy that the pattern observed for mdm-25A). By using as probe the human RNA-oligo 2, identical com-
plexes were detected in BCR/ABL-expressing mouse and hu- mRNA was similar to that for mY1 scRNA (Figure 5C, bottom
(lanes 2 and 3) or presence (lanes 4–6) of the competitor ssODNs shown in A; right, UV crosslinking with mouse (lanes 7–11) or human (lanes 12–15) 32P-labeled
RNA-oligo 2 and cytoplasmic extracts of BCR/ABL-expressing cells (32D-BCR/ABL and Ph1 K562), in the absence or presence of cold competitor (mouse or
human, as indicated) mdm2 exon 2 RNA-oligo 2. UV crosslinking of human RNA-oligo 2 with purified mdm2 RNA binding protein (lane 16), cytoplasmic
extracts of exogenous La-expressing 32Dcl3 cells (lane 17), La-immunodepleted and nondepleted K562 cytoplasmic extract (lanes 19 and 18), and
bacterially produced GST-La (lane 20) or GST-dn-hLa (226-348) (lane 21). *, the high molecular weight protein interacting with RNA-oligo 2 may correspond
to La homodimers.
C: Association of La with mdm2 mRNA. Equal aliquots of purified 32D-BCR/ABL total RNA isolated from the input (lane 2), anti-La, or preimmune serum
immunoprecipitates (lanes 5 and 6), and from the supernatants (lanes 3 and 4) of the immunoprecipitates, were assayed by RT-PCR to detect mdm2,
GRB2, U5 snRNA, and mY1 scRNA transcripts. The reaction in lane 7 contained anti-La immunoprecipitated RNA, but the RT enzyme mix was heat inactivated
prior to use; the reaction in lane 8 contained water instead of RNA.
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Figure 6. Effect of La antigen on MDM2 expression
A: Left: products of in vitro translation reactions programmed with no RNA (lane 1), luciferase control mRNA (lane 2), and equal amount of Ex.1/Ex.2-
(-86/-36) mdm2-HA mRNA lacking the La binding site (lane 3) and Ex.1 mdm2-HA mRNA (containing the La binding site) (lane 4). Right: In vitro translation
of full-length mdm2 mRNA (upper panel) in the absence (lane 1) or presence of bacterially purified GST-dn-hLa (lane 2) or GST only (lane 3). Lower panel
shows anti-GST Western blotting of in vitro translation reactions.
B and C: Expression of endogenous MDM2 (B) and ectopic HA-tagged MDM2 (C) in 32D-BCR/ABL cells retrovirally transduced with dn-hLa (226-348) or full-
length La cDNA as described in the text. As indicated, K562 cell extract was used as control for La expression.
D: Effect of La siRNAs on La and MDM2 expression in NIH3T3 cells. Untransfected cells (lane 1) and cells transfected with 50 nM (lane 2) or 100 nM (lane 3)
La siRNAs. hnRNP-K, hnRNP-A1, and GRB2 levels were monitored as control for possible nonspecific effects on other RNA binding proteins and for loading.
panel), which is known to be stably associated with La (Hendrick and Korneluk, 2000; Craig et al., 1997). Although this mutant
(dn-La) does not bind RNA (Figure 5B, lane 21), it retains theet al., 1981). Grb2 mRNA and U5 snRNA, the latter of which is
known not to be stably associated with La, served as negative La dimerization domain and has been used as a dominant-
negative mutant of La translation regulatory activity (Craig etcontrols (Figure 5C, middle panels). These results provide con-
vincing evidence that mdm-2 mRNA is specifically associated al., 1997). As shown in Figure 6A (right panel), synthesis
of 35S-labeled MDM2 was suppressed by this mutant (GST-with La in BCR/ABL-expressing myeloid precursor cells.
In vitro translation revealed that the 27-nucleotide sequence dn-hLa) but not by GST alone.
The effects of dn-hLa on MDM2 levels were also tested inthat interacts with La protein was required for efficient transla-
tion in rabbit reticulocyte lysate (RRL), since the mdm2 mRNA 32D-BCR/ABL cells retrovirally transduced with the MigR1-dn-
hLa retrovirus. Levels of endogenous MDM2 were approxi-lacking the La binding site (Ex.1/Ex.2 [-86/-36] mdm2-HA
mRNA) was much less efficiently translated than a mdm2 mRNA mately 75% lower in GFP-positive cells expressing dn-hLa than
in cells transduced with the empty vector (Figure 6B). The domi-deletion mutant containing it (Ex.1 mdm2-HA mRNA) (Figure
6A, left panel). Since addition of purified hLa protein to this nant-negative La also suppressed expression of HA-tagged
MDM2 in 32D-BCR/ABL cells transduced with Ex.1-mdm2-reaction had little stimulatory activity, we tested the effect of
La antigen on mdm2 mRNA translation by using a truncated La HA (Figure 6C). In complementary experiments, expression of
endogenous MDM2 was upregulated in 32D-BCR/ABL cells(amino acids 226–348) protein that has been previously charac-
terized as a useful tool to study La-dependent translation (Holcik transduced with the full-length mouse La cDNA (Figure 6B).
152 CANCER CELL : FEBRUARY 2003
A R T I C L E
Figure 7. Effect of La antigen on adriamycin sensitivity of 32D-BCR/ABL cells
A: Number of viable 32D-BCR/ABL, dn-La-expressing 32D-BCR/ABL (32D-BCR/ABL dn-hLa), and dn-La/mdm2-HA coexpressing 32D-BCR/ABL cells (32D-BCR/
ABL dn-hLa/mdm2-HA) after adriamycin treatment.
B: Number of viable 32D-BCR/ABL and wild-type La-expressing 32D-BCR/ABL (32D-BCR/ABL WT-mLa) cells after adriamycin treatment. Error bars reflect
three different experiments; inset shows MDM2 protein levels in 32D-BCR/ABL, 32D-BCR/ABL dn-hLa, and 32D-BCR/ABL dn-hLa/mdm2-HA.
Since the La binding site is required for efficient mdm2 mRNA mononuclear CML and BCR/ABL-expressing cells treated with
STI571 (1 M; 24 hr) (Figure 8). STI571 treatment suppressedtranslation in vitro (Figure 6A) and for BCR/ABL-dependent
MDM2 expression in vivo (Figure 4B), the results shown in Figure La antigen expression in 32D-BCR/ABL cells (Figure 8A, lanes
1–3), in the Philadelphia1 myeloid blast crisis cell lines EM-36B and 6C establish a functional link between the La binding
site in mdm2 RNA and the positive effects of La on MDM2 (Figure 8B) and K562 (not shown), and in CD34 cells from a
CML-AP patient (Figure 8, lanes 12 and 13). In addition, Laexpression. The functional link between La expression and
MDM2 levels was further strengthened by RNA interference in mRNA levels were similar in parental, untreated, and STI571-
treated (1 M; 48 h) BCR/ABL-expressing myeloid precursorNIH3T3 cells, in which the uptake of small interfering RNAs
(siRNAs) is several folds higher than in myeloid cells. As shown cells (not shown), while the stability of newly synthesized
35S-labeled hLa protein was markedly diminished in myeloidin Figure 6D, La expression was specifically downmodulated
upon NIH3T3 transfection with a mix of siRNAs corresponding blast crisis EM-3 cells treated with STI571 (t1/2hLa EM-3  19.8
hr; t1/2hLa EM-3STI571  11 hr) (Supplementary Figure S2 atto nucleotides 310–610 of human La mRNA. Levels of two addi-
tional RNA binding proteins, hnRNP-K and hnRNP-A1, which http://www.cancercell.org/cgi/content/full/3/2/145/DC1), sug-
gesting that BCR/ABL enhances La expression by activatingare involved in the regulation of different aspects of mRNA
metabolism including mRNA translation (Iervolino et al., 2002; signaling pathways leading to increased La protein stability.
Indeed, in EM-3 (Figure 8B) and in 32D-BCR/ABL (not shown)Habelhah et al., 2001), were not affected (Figure 6D). The down-
modulation of La expression was associated with a marked and cells treated with inhibitors of known BCR/ABL-activated path-
ways, La levels were markedly downmodulated by the specificspecific decrease in MDM2 levels (Figure 6D).
32D-BCR/ABL cells expressing the dn-hLa were more sensi- phospholipase C- (PLC-) inhibitor U73122, but not by its
inactive U73343 derivative and, to a lesser degree, by stauro-tive to adriamycin than parental cells (Figure 7A). At three differ-
ent drug concentrations, there was approximately a 50% differ- sporin and by the PI-3K inhibitor LY294002 (Figure 8B). By
contrast, treatment of EM-3 cells with inhibitors of MAPK, S6Kence in the number of viable cells between 32D-BCR/ABL and
32D-BCR/ABL-dn-hLa cells. The reduced cell number reflected and PKC kinases did not affect La expression (Figure 8B).
Expression of the La antigen was more abundant in mononu-an increased frequency of apoptotic cells and a reduced propor-
tion of cycling cells (not shown). Ectopic expression of HA- clear CML-BC and CML-APCD34 than in mononuclear CML-CP
samples (Figure 8C, lanes 5–11), and increased during CMLtagged MDM2 rendered these dn-hLa-expressing cells similar
to parental 32D-BCR/ABL cells in their susceptibility to adriamy- disease progression (Figure 8C, compare lanes 1–2 and lanes
3–4). Indeed, the pattern of La antigen expression in CML sam-cin-induced apoptosis (Figure 7A), consistent with an MDM2-
dependent effect of the dominant-negative La expression. By ples correlates with that of MDM2 (see Figure 2) and of BCR/
ABL that is also more abundant in patient-derived CML-BCcontrast, 32D-BCR/ABL cells overexpressing wild-type mouse
La cDNA and exhibiting increased levels of MDM2 were more samples (not shown). Thus, levels of BCR/ABL, La antigen, and
MDM2 appear to be functionally linked.resistant than parental cells to adriamycin-induced apoptosis
(approximately 50% increase in viable cell numbers) (Figure 7B).
Discussion
Effect of BCR/ABL on La expression
To assess whether expression of the La antigen correlates with During disease progression, CML progenitor cells acquire a
number of genetic alterations that may explain the aggressivethat of MDM2 and is regulated in a BCR/ABL-dependent man-
ner, Western blots were performed on total cell lysate of primary phenotype, chemotherapeutic drug resistance, and poor prog-
CANCER CELL : FEBRUARY 2003 153
A R T I C L E
Figure 8. Effect of BCR/ABL on La expression
Effect of STI571 on La protein levels in 32D-BCR/
ABL (A, lane 3), EM-3 (B) and CML-AP (C, lane
13) cells. Effect of different inhibitors of BCR/ABL
activated pathways on La protein levels (B). Ex-
pression of La in patient-derived CML-CP, CML-
AP (CD34 and CD34 fractions) and CML-BC
primary mononuclear cells (C).
nosis of CML-BC. The p53 gene is genetically inactivated in a pressing its transactivating function (Momand et al., 1992; Thut
et al., 1997; Wadgaonkar and Collins, 1999). According to acohort of CML-BC patients (Feinstein et al., 1991), and the p53
null background promotes a rapidly fatal disease process in previous study (Ries et al., 2000), BCR/ABL might have led to
increased transcription of mdm2 due to RAS-dependent effectsmouse models of BCR/ABL-dependent leukemogenesis (Skor-
ski et al., 1996b; Honda et al., 2000). Although other genetic (Ries et al., 2000; Cortez et al., 1995; Skorski et al., 1994);
however, we found that mdm2 mRNA levels were comparableabnormalities (e.g., chromosome 8 trisomy) (Kantarjian et al.,
1993; Osarogiagbon and McGlave, 1999; Sawyers, 1999) may in parental and BCR/ABL-expressing cells and were only slightly
downregulated after STI571 treatment. This suggested that theact independently of p53, p53 may be functionally inactivated
in some CML-BC patients carrying a wild-type p53 gene. Since increased MDM2 levels in BCR/ABL-expressing cells are pri-
marily dependent on posttranscriptional mechanisms, consis-a double Philadelphia chromosome is also a common secondary
genetic alteration in CML-BC (Kantarjian et al., 1987) and levels tent with a previous report (Goetz et al., 2001), although in that
case it was unclear whether this reflected enhanced MDM2of BCR/ABL often increase during disease progression (Gaiger
et al., 1995; Elmaagacli et al., 2000), we assessed whether stability, synthesis, or both (Goetz et al., 2001). BCR/ABL has
been shown to regulate protein levels by promoting or sup-increased levels of BCR/ABL leads to downregulation of p53
expression, and if so, by which mechanism(s). pressing proteasome-dependent degradation (Dai et al., 1998;
Perrotti et al., 2000). Our data demonstrated that the half-lifeIn 32Dcl3 myeloid progenitor cells p53 levels were downreg-
ulated by expression of BCR/ABL. This did not reflect altered of MDM2 was essentially identical in parental and BCR/ABL-
expressing cells, indicating that inhibition of proteasome-expression of p19ARF (not shown), but instead correlated with
increased MDM2 expression, suggesting that p53 is functionally dependent degradation does not account for increased MDM2
expression in BCR/ABL-expressing cells. Newly synthesizedinactivated by its negative regulator MDM2. Indeed, proteasome
and nuclear export inhibitors raised p53 levels in these cells, MDM2 was higher in BCR/ABL-expressing than in parental cells,
suggesting that translational regulation is a critical mechanismconsistent with an enhanced pathway of MDM2-mediated p53
degradation. MDM2 is overexpressed in more than 50% of my- contributing to the increased MDM2 levels in these cells.
Translational regulation of MDM2 expression was first sug-eloid and lymphoid leukemias and correlates with poor progno-
sis (Seliger et al., 1996; Faderl et al., 2000; Zhou et al., 1995, gested on the basis of in vitro and in vivo assays demonstrating
different usage of in-frame translation initiation codons (Barak2000), but p53 expression is not always downregulated in these
samples. Since expression of a more stable, mutant form of et al., 1994). Subsequently, Brown et al. (1999) demonstrated
that the two uORFs included in the 5 UTR of mdm2 mRNAp53 is only detected in some of these cases (Faderl et al., 2000;
Zhou et al., 1995), the increased levels of MDM2 in leukemic inhibit translation when linked to reporter genes. Moreover, cer-
tain tumor cell lines overexpressing MDM2 exhibit enhancedcells may not be sufficient to induce degradation of wild-type
p53. Thus, MDM2 may antagonize p53 by functionally sup- translation and efficient polysome loading of mdm2 mRNA
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(Brown et al., 1999; Landers et al., 1994; Capoulade et al., (Wolin and Cedervall, 2002). Interestingly, expression of XIAP
was downmodulated in STI571-treated BCR/ABL-expressing1998), consistent with the existence of translation-regulatory
mechanisms leading to MDM2 overexpression. Our studies sug- cells (Fang et al., 2000a), suggesting that, in these cells, MDM2
and XIAP levels might be in part coregulated by La. Consistentgest that in BCR/ABL-expressing cells, translation of mdm2
mRNA is not differentially influenced by the uORFs, but rather with this, La is abundant in CML-BC primary samples, and its
levels appear to correlate with BCR/ABL levels and tyrosineis dependent on a 27-nucleotide sequence located in the central
part of the mdm2 exon 2 (intercistronic region). Mouse and kinase activity. The observation that treatment with STI571
downregulates La protein expression by decreasing its stabilityhuman mdm2 exons 2 are conserved in size but are widely
divergent in sequence except for a short region in its central is noteworthy, because it was thought that La levels are constitu-
tive (Maraia and Intine, 2001; Wolin and Cedervall, 2002). More-portion (Figure 5). The importance of this conserved region was
revealed by its requirement for efficient mdm2 expression both over, La expression was downmodulated by a specific PLC-
inhibitor and, to a lesser degree, by the serine/threonine kinasein vitro and in vivo. RNA probes and UV crosslinking identified
a 50 kDa RNA binding protein present in mouse and human (PKA, PKC, PKG, and CaM kinase) inhibitor staurosporin and
by a PI-3K inhibitor. Since PLC- is activated by BCR/ABLBCR/ABL-expressing cells that interacts specifically with the
conserved part of mdm2 exon 2 mRNA. Since the results sug- (Gotoh et al., 1994) and is required for the activation of several
PKC isoforms (Newton, 1995), it is possible that BCR/ABL-gested that the identified RNA binding protein might reflect the
action of an mdm2 mRNA translation-stimulatory factor, this dependent activation of a specific PKC isoform (PKCI/II ex-
cluded) plays a role in regulating La levels. Of interest, the Laprotein was purified on the basis of its ability to interact with the
conserved sequence tract in mdm2 mRNA and was identified as protein is phosphorylated by PKC in HeLa cells (Broekhuis et
al., 2000). However, it is unknown whether PKC phosphorylationthe La antigen. Indeed, mdm-2 mRNA appears to be stably
associated with La in BCR/ABL-transformed cells, since La im- of La protein also occurs in BCR/ABL-expressing cells and
whether it is involved in the upregulation of La levels.munodepletion abolished binding to mdm2 mRNA in REMSA
(Figure 5B) and mdm2 mRNA recovery from the anti-La immuno- That the PI-3K inhibitor LY294002 also downmodulates La
protein levels suggests the involvement of an additional path-precipitate was comparable to that of mY1 scRNA (Figure 5C),
a small cytoplasmic RNA that is stably associated with La (Hen- way(s), although it cannot be excluded that interference with
PDK1 plasma membrane translocation (which is regulated in adrick et al., 1981).
This is not the first example of an RNA binding protein whose PI-3K-dependent manner) prevents PKC activation (Le Good et
al., 1998).translation-regulatory activity is modulated by BCR/ABL. In fact,
we recently reported that BCR/ABL induces, in a tyrosine ki- The data described in this report indicate that La has a
direct and positive effect on MDM2 expression because: (1) Lanase-dependent manner, the expression of the RNA binding
protein hnRNP E2 that is directly responsible for translational recognizes a specific conserved sequence tract in mdm2 mRNA
that is required for efficient MDM2 expression in vitro and insuppression of C/EBP	, the major regulator of granulocytic dif-
ferentiation (Perrotti et al., 2002). vivo; (2) a dominant-negative (dn) La mutant inhibited mdm2
mRNA translation in vitro and suppressed MDM2 levels in BCR/Although the La antigen is mostly nuclear, where it is in-
volved in the biogenesis of RNA polymerase III transcripts and ABL-expressing cells; (3) downregulation of La expression by
siRNAs led to a marked decrease in MDM2 levels; and (4) over-processing of tRNA precursors, it is also present in the cyto-
plasm, and increases there under certain conditions (Wolin and expression of wild-type La led to an increase in MDM2 ex-
pression.Cedervall, 2002; Fan et al., 1998). For example, in poliovirus-
infected cells, La is redirected to the cytoplasm, where it is Purified hLa protein had little stimulatory affect on in vitro
translation of mdm2 mRNA; this may be explained by the pres-believed to interact with the 5 UTR of poliovirus mRNA to
positively influence its translation (Maraia and Intine, 2001; Wolin ence of endogenous rabbit La in the reticulocyte lysate (Holcik
and Korneluk, 2000, and data not shown), the low affinity ofand Cedervall, 2002, and references therein). In addition to mul-
tiple virus-derived mRNAs (Maraia and Intine, 2001; Wolin and GST-La for the mdm2 5 UTR, or the need for posttranslational
modifications possibly occurring in BCR/ABL-transformed cells.Cedervall, 2002), La has also been reported to interact with
cellular mRNAs. Recently, the La antigen was reported to acti- With regard to the latter possibility, we note that while serine
366, the major phosphorylation site in human La, has beenvate IRES-dependent translation of the immunoglobulin heavy
chain binding protein (BiP) mRNA upon interaction with its 5 shown to affect binding to precursor tRNAs (Intine et al., 2000),
phosphorylation that occurs on three other sites has not beenUTR (Kim et al., 2001). Remarkably, the only significant homol-
ogy (70% identity) between mdm2 and BiP mRNA 5 UTRs associated with any known activity of La (Broekhuis et al., 2000),
leaving open the possibility that La phosphorylation may pro-is in the core sequence conserved in human and mouse mdm2
5 UTR reported here, and this includes the region of BiP mRNA mote a stimulation of mdm2 mRNA translation.
That a La-mediated effect on MDM2 expression is function-that has been shown to interact with La. La antigen was also
identified as part of a multiprotein complex interacting with the ally relevant for BCR/ABL leukemogenesis is indicated by the
changes in susceptibility of BCR/ABL-expressing cells to adria-IRES region of XIAP mRNA that is required for its translation in
vitro and in vivo (Holcik and Korneluk, 2000). The segment of mycin-induced apoptosis, as wild-type La-overexpressing cells
were more resistant than parental cells, whereas cells express-the mdm2 5 UTR bound by the La protein did not function as
IRES when driving GFP expression in BCR/ABL-expressing cells ing dn-La were more sensitive. Although MDM2 levels were
markedly downmodulated in 32D BCR/ABL cells expressingtransduced with a bicistronic retrovirus (not shown; see Supple-
mentary Figure S1 at http://www.cancercell.org/cgi/content/ dn-La, these cells neither exhibited spontaneous apoptosis nor
altered cell cycle activity (not shown). This is consistent withfull/3/2/145/DC1), consistent with the possibility that the La pro-
tein has a more general role in the regulation of mRNA translation the primary role of MDM2 as a regulator of p53 and suggests
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infect parental and BCR/ABL-expressing cells; 24 hr later, infected cellsthat the proposed p53-independent effects of MDM2 (Sigalas
were cultured in the presence of neomycin (1 mg/ml) or puromycin (2 g/ml)et al., 1996) might not be important in BCR/ABL-expressing
for clonal selection, or sorted (EPICS Profile Analyzer, Coulter Inc., Hialeah,cells.
FL) for green fluorescent protein (GFP) expression.
In summary, we have demonstrated that the expression of
MDM2 is upregulated in BCR/ABL-expressing cells via en- Plasmids
hanced translation that is dependent on increased levels of the WT-uORF-, Ex.1-, Ex.1/Ex.2(-86/-36)-, Ex.1/Ex.2(-86/-62)-, and
Ex.1/ Ex.2-mdm2-HA: The 5 UTR region of mdm2 cDNA, containing theRNA binding protein La and its direct interaction with a short
nucleotides corresponding to exons 1 and 2 or deletions of these sequences,segment of mdm2 5 UTR. While a role for the La antigen in
and part of the mdm2 coding sequence (cds) were obtained by RT-PCRmRNA metabolism has previously been suggested (Maraia and
amplification using an upstream primer containing a XhoI site at the 5-endIntine, 2001), our studies establish a link between La expression
and a downstream primer spanning the BamHI site of the mdm2 cds. The
and the phenotype of hematopoietic cells transformed by an remaining mdm2 cds was PCR-generated from the full-length murine mdm2
oncogenic tyrosine kinase, and suggest that La-dependent cDNA (kind gift of Donna L. George, University of Pennsylvania, School of
MDM2 upregulation may contribute to progression of CML into Medicine, Philadelphia, PA) using an upstream primer spanning the BamHI
site of mdm2 cds, and a downstream primer containing the last 23 nucleo-blast crisis.
tides of the cds, a hemagglutinin (HA)-tag preceding the mdm2 stop codon,
and an EcoRI site. PCR products were XhoI/BamHI or BamHI/EcoRI-Experimental procedures
digested and subcloned directionally into the XhoI/EcoRI sites of the bicis-
tronic IRES-GFP MigRI retroviral vector (Pear et al., 1998).Cell cultures and primary CML cells
MSCV Ex.1 mdm2-HA: MIG RI Ex.1 mdm2-HA was digested withMurine IL-3-dependent 32Dcl3 myeloid precursor cells and derivative cell
XhoI-EcoRI and the released fragment was cloned into the XhoI-EcoRI di-lines were maintained in culture in IMDM medium supplemented with 10%
gested MSCVpuro retroviral vector.heat-inactivated FBS (Sigma Chemical Co., St. Louis, MO), 2 mM L-gluta-
pcDNA3 Ex.1 mdm2-HA: MigRI Ex.1 mdm2-HA was digested withmine (Gibco, BRL, Gaithersburg, MD), and 10% WEHI-conditioned medium
BglII-EcoRI-and the released fragment was cloned into the BamHI-EcoRI-as a source of IL-3.
digested pcDNA3 plasmid.The EM-3 myeloid blast crisis cell line (Lubbert et al., 1988) was kindly
pcDNA3 Ex.1/Ex.2(-86/-36) mdm2-HA: MigRI Ex.1/Ex.2 (-86/-36)provided by Dr. A. Keating (Ontario Cancer Center, Toronto, Canada).
mdm2-HA was digested with BglII-EcoRI-and the released fragment wasFicoll-separated mononuclear marrow (or peripheral) hematopoietic
cloned into the BamHI-EcoRI-digested pcDNA3 plasmid.cells of patients with CML in chronic phase (CML-CP), accelerated phase
pGEX-2T-hLa (1-408) and pGEX-2T-dn-hLa (226-348) were the kind gift(CML-AP), and myeloid blast crisis (CML-BC) were cultured overnight in
of N. Sonenberg (McGill University, Montreal, Canada).IMDM with 20% FBS, 2 mM L-glutamine supplemented with human recombi-
MigR1 hLa: the coding sequence of hLa was obtained by BamHI/EcoRInant IL-3 (20 ng/ml), IL-6 (20 ng/ml), Flt-3 Ligand (100 ng/ml), and SCF (100
digestion of the pGEX-2T-hLa plasmid and directionally subcloned into theng/ml) (StemCell Technologies Inc., Vancouver, Canada). CML-CP #12–13
BglII-EcoRI-digested MigR1 vector.and CML-BC #12–13 were from two patients with CML in chronic phase
MigR1 mLa: full-length mouse La cDNA (Topfer et al., 1993) (kind giftand after progression into blast crisis, respectively. CD34 cell separation
of James McCluskey, Flinders Medical Center, Bedford Park, South Austra-was performed using a MACS CD34 Kit (Miltenyi Biotec., Auburn, CA). Stable
lia) was cloned into the EcoRI site of the MigR1 retrovirus.phase CML samples were provided by Dr. A.M. Gewirtz (Dept. of Medicine,
MigR1 dn-hLa (226–348) and MSCVdn-hLa (226–348): the La cDNAUPenn, Philadelphia, PA) and by the Cancer and Leukemia Group B Leuke-
fragment encoding amino acids 226–348 was PCR amplified from the pGEX-mia Tissue Bank (OSU, Columbus, OH). Accelerated and blastic phase CML
2T-dn-hLa plasmid using a 5 primer that includes a BglII restriction site,samples were provided by Drs. N. Flomenberg (Bone Marrow Transplant
the ATG codon, and 18 nucleotides corresponding to amino acids 226–231,Unit, TJU, Philadelphia, PA) and A.M. Gewirtz. Sample from patients at
and a 3 primer that includes 18 nucleotides corresponding to amino acidsdifferent stages of CML were provided by Dr. C. Gambacorti-Passerini (Ex-
343–348, the TAA stop codon, and the EcoRI restriction site. After BglII/perimental Oncology, NCI, Milano, and Hematology Section, S. Gerardo
EcoRI digestion, the product was cloned directionally in the BglII/EcoRI-Hospital, Monza, Italy).
digested MigR1 or MSCV-puro vector.Where indicated, parental and BCR/ABL-expressing 32Dcl3 cells were
SK Ex.2 mdm2: mdm2 exon 2 was amplified by PCR from MigR1 WT-treated for the indicated times with 10 M lactacystin (Calbiochem, San
uORF mdm2-HA using a 5 primer which includes the XhoI restriction siteDiego, CA), 25 M ALLN (Calbiochem), 5 ng/ml Leptomycin B (kindly pro-
and a 3 primer which includes the EcoRV restriction site. After XhoI/EcoRVvided by Novartis Pharma AG, Basel, Switzerland), 20 g/ml cycloheximide
digestion, the product was cloned into the XhoI/EcoRV-digested SK blue-(Sigma) or 1 g/ml adriamycin (APP, Inc.). To inhibit BCR/ABL tyrosine
script plasmid.kinase activity, 32D-BCR/ABL, EM-3 cells or CD34 CML-AP cells were
cultured for the indicated time in medium supplemented with the ABL-kinase
Western blot analysis, immunoprecipitation,inhibitor STI571 (1–2 M) (kindly provided by Novartis Oncology).
and metabolic labelingWhere indicated, EM-3 cells were treated with kinase inhibitors (16 to
Cells were harvested, washed once with ice-cold PBS, and lysed (107 cells/24 hr) used at the following concentrations: rapamycin, 15 nM (Calbiochem,
100 l lysis buffer) in hypertonic buffer (1% NP-40, 0.5 M NaCl, 10 mMSan Diego, CA); PD098059, 50 M (Calbiochem); LY294002, 25 M (Calbio-
Hepes [pH 7.5], 10% glycerol supplemented with protease and phosphatasechem); staurosporin, 1 M (Calbiochem); hispidin (PKC inhibitor), 5 M
inhibitors [1 mM phenylmethylsulfonylfluoride {PMSF}, 25 g/ml aprotinin,(Calbiochem); U73122, 1 M (Biomol); U73343, 1 M (Biomol).
10 g/ml leupeptin, 100 g/ml pepstatin A, 5 mM benzamidine, 1 mMThe amphotropic-packaging cell line Phoenix E (Dr. G. P. Nolan, Stan-
Na3VO4, 50 mM NaFl, 10 mM -glycerol-phosphate]). For nuclear fractionsford University School of Medicine) was maintained in culture in DMEM/
preparation, cells were lysed in buffer A (20 mM Hepes [pH 7], 10 mM10% FBS medium and grown for 16–18 hr to 80% confluence prior to
KCl, 2 mM MgCl2, 0.5% NP-40) supplemented with the protease inhibitorstransfection by calcium phosphate-DNA precipitation (ProFection system,
described above, homogenized, and nuclei were sedimented at 1500 
 gPromega, Madison, WI).
for 2 min. The nuclear pellet was washed three times in buffer A, resuspended
in the same buffer containing 0.5 M NaCl, rocked gently for 30 min at 4C,Retroviral infection of parental and BCR/ABL-expressing
32Dcl3 cells and clarified by centrifugation (15,000 
 g, 10 min). For direct lysis, cells
(2–3 
 105 ) were washed once with ice-cold PBS and directly lysed in32Dcl3-derivative cell lines expressing pSR	MSVtKneo-p210BCR/ABL, the
MSCVpuro-, and/or the MigRI-based plasmids were generated by retroviral 20 l of Laemmli buffer. Immunoprecipitation and Western blotting were
performed as described (Perrotti et al., 2000).infections of parental and BCR/ABL-expressing 32Dcl3 cells as described
(Pear et al., 1998). Briefly, infectious supernatants from transiently trans- Antibodies used were: monoclonal anti-p53 (Ab-1, Calbiochem); mono-
clonal anti-MDM2 2A10 (kind gift of Dr. A. J. Levine, The Rockefeller Univer-fected Phoenix cells were collected 48 hr after transfection and used to
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sity, New York, NY); monoclonal anti-HSP90 (Transduction Laboratories); CGGAUCACC-3) of mouse mdm2 mRNA, or 35 mer oligoribonucleotide
corresponding to the human homolog of mouse RNA-oligo 2. Reactionsmonoclonal anti-phosphotyrosine PY20 (Transduction Laboratories); mono-
clonal anti-c-Abl (Ab-3, Calbiochem); monoclonal anti-HA (Babco, Rich- were incubated for additional 20 min with 10 mg/ml heparin (Calbiochem)
to reduce nonspecific binding. After UV crosslinking (3,500 J 
 100, 30mond, CA); monoclonal anti-GRB2 (Transduction Laboratories); monoclonal
anti-p21 (Santa Cruz Biotechnology, Santa Cruz, CA); monoclonal anti-His- min at room temperature), RNA-protein complex(es) were resolved by a
4%–15% or a 7.5% SDS-PAGE. In competition assays, RNA-protein bindingtone H1 (Santa Cruz Biotechnology); monoclonal anti-hLa (Transduction
Laboratories), and anti-human La (Go) serum (Intine et al., 2002). anti-hnRNP reactions were performed in the presence of a 1000-fold molar excess of the
A1 and anti-hnRNP K antibodies were kindly provided by Dr. G. Dreyfuss (murine or human) RNA-oligo 2 or of single-stranded oligodeoxynucleotides
(University of Pennsylvania, Philadelphia, PA). corresponding to different segments of mdm2 exon 2: ssODN1 (5-AGCCGT
For metabolic labeling, 32Dcl3 and 32D-BCR/ABL cells were washed CTGCTGGGCGAGCGGGAGACCGACCGGAC-3), ssODN2 (5-GACCGGA
four times with PBS and cultured (2 
 106 cells/ml) for 60 min in methionine- CACCCCTGGGGGACCCTCTCGGATCACC-3), ssODN3 (5-GGATCACC-
free RPMI 1640 supplemented with 10% dialyzed FBS (Gibco BRL, NY) and GCGCTTCTCCTGCGGCCTCCAGGCCAA-3). La-depleted K562 cyto-
2 ng/ml recombinant murine IL-3 (R&D Systems Inc., Minneapolis, MN). plasmic extracts were obtained by immunodepletion using anti-La (Go) hu-
Cells were washed and resuspended (5
 106 cells/ml) in medium containing man IgG coupled to protein G sepharose (Intine et al., 2002).
200 Ci/ml of [35S]-methionine (NENTM, Life Science Products, MA). After 90
min, cells were washed twice with cold Hank’s solution and lysed in hyper- Purification of mdm2 mRNA binding protein
tonic buffer. Precleared lysates were incubated at 4C for 2 hr with protein The mdm2 5UTR RNA binding protein was purified by RNA affinity chroma-
G-agarose (Oncogene Research Products, MA)-coupled anti-MDM2 anti- tography using approximately 500 mg of cytoplasmic extracts from K562
body. Immunoprecipitated proteins were resolved by SDS-PAGE under re- cells (Perrotti et al., 2002). After concentration by Centriprep-10 (Millipore),
ducing conditions, transferred onto nitrocellulose and visualized after expo- cytoplasmic extracts (70 mg/ml) in binding buffer were size-fractionated
sure to X-AR films (Eastman Kodak Co., Rochester, NY). using a Sephacryl S-200 column (0.4 ml/min; bed volume 120 ml) equilibrated
in the same buffer. Fractions retaining the ability to bind the mdm2 32P-RNA-
Isolation of polysome/monosome-associated RNA from untreated oligo 2 in UV-crosslinking were loaded on a Hi-Trap heparin-sepharose
and STI571-treated BCR/ABL-expressing cells column (Amersham Pharmacia Biotech), and the eluted fractions retaining
RNA was prepared as described (Fu et al., 1996), with minor modifications. the RNA binding activity were further purified by RNA affinity chromato-
Briefly, untreated or STI571 (2 M, 12 hr)-treated 32D-BCR/ABL cells (108 ) graphy.
were washed twice in ice-cold Tris-saline solution (25 mM Tris-HCl [pH 7.5], Briefly, 100 g of the 5-biotynilated mdm2 RNA-oligo 2 was coupled to
25 mM NaCl) containing 10 mM MgCl2 and 10 g/ml cycloheximide and a streptavidin-sepharose resin according to the manufacturer’s instructions
lysed on ice in 1 ml of extraction buffer (1 mM Tris-HCl [pH 7.5], 140 mM (Amersham Pharmacia Biotech). Fractions containing the mdm2 RNA binding
NaCl, 1.5 mM MgCl2, 0.5% NP-40, 665 g/ml heparin, 1 mM PMSF, 150 protein were passed through the RNA-affinity column equilibrated in binding
g/ml cycloheximide, 20 mM dithiothreitol, 500 U/ml RNasin). Lysates were buffer at a flow rate of 0.1 ml/min. After collecting the flow-through, the
nuclei-depleted, clarified by centrifugation (14,000 rpm, 5 min at 4C) and column was washed with 10 volumes of binding buffer supplemented with
layered onto a 15%–50% linear sucrose gradient (10 ml) prepared in extrac- 1 mg/ml of heparin followed by 10 volumes of binding buffer, and purified
tion buffer (without NP-40 and PMSF). The gradients were centrifuged in an proteins eluted with a salt gradient (0.5–2 M NaCl). After dialysis in binding
SW41 Beckman rotor at 38,000 rpm for 120 min at 4C. Fourteen fractions buffer, the affinity-purified fractions were tested by UV crosslinking, gel-
of equal volume (750 l) were collected from the bottom of the tubes. During fractionated, and stained with Coomassie blue. A gel slice from a preparative
fractionation, polysome profiles were monitored with a simultaneous A254 SDS-PAGE containing the purified protein was digested and sequenced
trace. RNA was prepared from each fraction by phenol/chloroform extraction by microcapillary reverse-phase high-performance liquid chromatography
and isopropanol precipitation. RNA was washed with ethanol and resus- nanoelectrospray tandem mass spectrometry (mLC/MS/MS) on a Finnigan
pended in 30 l of DEPC-treated water. LCQ DECA quadrupole ion trap mass spectrometer (Microchemistry Facility
of Harvard University, Cambridge).
Northern blot analysis and RT-PCR
Total RNA was extracted using Tri-Reagent (Molecular Research Center, Inc., RT-PCR of coimmunoprecipitated RNA
OH). For Northern blot analysis, total RNA (10 g) or polysome-/monosome- 1 ml of whole cell extract was made from 30 ml of 32D-BCR/ABL cells
associated RNA (5 g/fraction) was fractionated onto denaturing 1% aga- grown to a density of 8.0 
 105 /ml. Immunoprecipitations (IPs) were per-
rose/6.6% formaldehyde gels, transferred onto Hybond-nylon membrane formed using 50 l of anti-La (Go) or nonimmune sera and 25 l of protein
(Amersham Pharmacia Biotech, Inc.), and hybridized to 32P-labeled cDNAs A sepharose (PAS) as described (Steitz, 1989). Briefly, after conjugation, the
probes specific for murine mdm2, murine p53, or hLa. RT-PCR amplification IgG-PAS beads were washed four times with 1 ml of NET-2 and incubated
of mdm2 mRNA was carried from total RNA using mdm2 (mouse or human) with 50 l of precleared extract in a final volume of 200 l NET-2 for 3 hr
specific primers. For detection of ectopic HA-tagged mdm2 mRNA in retrovi- at 4C with rotation. The IgG-PAS beads were spun out and the supernatant
rus-transduced cells, we used a 5 primer (5-TTGAAGGAGGAAACGCA was collected. The beads were then washed six times with 1 ml of cold
GCA-3) corresponding to nucleotides 1438–1457 of mouse mdm2 cDNA NET-2. The beads were extracted twice with 100 l of 50 mM Tris-Cl (pH
and a 3 primer (5-TCTTAAGCGTAATCTGGAACAT-3) complementary to 7.5), 2% SDS followed by 200 l of H2O. Total RNA was purified from
part of the HA sequence. BCR/ABL levels were determined by PCR as equivalent amounts of the supernatants and input, as well as from all of the
described (Perrotti et al., 2002). GRB2 mRNA levels were monitored as immunoprecipitated material using guanidinium thiocyanate, phenol, and
control for equal loading. chloroform, followed by ethanol precipitation such that the final volume of
precipitated slurry for each sample was 750 l. RT-PCR was performed
using the Titan One tube RT-PCR System (Roche). For each of the RNAsRNA UV crosslinking
Cytoplasmic extracts were prepared and used for UV crosslinking as de- assayed, equal aliquot of purified RNA samples were dissolved in 25 l of
0.2 mM dNTPs, 5 mM DDT, 20 M each primer, and 5 U RNasin and addedscribed (Perrotti et al., 2002). Briefly, 107 cells were lysed in 100 l of binding
buffer [10 mM HEPES-KOH {pH 7.5}, 14 mM KCl, 3 mM MgCl2, 5% glycerol, to a reaction tube with 25 l of 1X RT-PCR buffer (with Magnesium) and 1
l of enzyme mix. For the reactions containing heat inactivated AMV reverse0.2% NP-40, 1 mM DTT, 1 mM PMSF, 25 g/ ml aprotinin, 10 g/ml leupep-
tin, 10 g/ml pepstatin A, 5 mM benzamidine, 1 mM Na3VO4, 50 mM NaF transcriptase, the enzyme mix was heated to 95C for 2 min before addition.
Reaction conditions were as follows: for GRB2 and mY1; 30 min at 50C,and 10 mM -glycerolphosphate] and the cytoplasmic fraction purified by
centrifugation (2 min at 8500 
 g at 4C). Cytoplasmic proteins (15 g) were 2 min at 95C, followed by 22 cycles of 10 s at 95C, 30 s at 58C, and 45 s
at 68C; for mdm2 and U5, 25 cycles were used. Equal aliquots of theincubated (30 min at room temperature) with 6.25 
 103 cpm of a 89 bp
riboprobe corresponding to mdm2 exon 2 (made by T7-directed in vitro products were electrophoresed on a 2.5% agarose gel for 45 min at 50 V.
Primers (5 to 3): mdm2: TTCTCCTGCGGCCTCCAGGC and AGCAATGGtranscription from the EcoRV-linearized SK-Ex.2 mdm2 plasmid) or 35 mer
oligoribonucleotide (murine RNA-oligo 2) corresponding to nucleotides 61 TTTTGGTCTAACCAGA; mY1: GGCTGGTCCGAAGGTAGTG and AAAGAC
TAGTCAAGTGCAGTAGTGAGA; U5: GATACTCTGGTTTCTCTTCAGATCGto 27 (relative to the ORF) (5-GACCGGACACCCCUGGGGGACCCU-CU
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